Silence Therapeutics plc
SLN
NASDAQ·Healthcare·Biotechnology·Mkt cap $689.1M
$14.59
▼ -1.35%
P/E
-24.32
Mkt Cap
$689.1M
52-Wk Range
$4.19–$17.58
52-Week Range
$4.19 - $17.58
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 171.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
Moderate growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+134.2% over 3m
Quality
Strong
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying SLN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 10, 2026
Reported EPS of -$0.26 vs -$0.14 consensus (-87.5% surprise). Revenue of $137.2K vs $1.1M expected (-87.8%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-87.5%
Revenue trend · last 2Q
—
—
Q1 26
Q2 26
$421.3K
$0
Margins · last 2Q
Profit
—
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Cantor Fitzgerald · Jun 24, 2026
vs Industry
How SLN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.